TB Vaccines

Cytokine-Secreting BCG May Offer Improvement

Published in TB and Outbreaks Week, February 19th, 1996

Cytokine-secreting bacillus Calmette-Guerin can enhance immune response to mycobacterial antigens and may be improved reagents for tuberculosis vaccination and cancer therapy, according to a report from Massachusetts.

BCG is among the most widely used human vaccines, mainly because it requires only a single inoculation, it can be given at birth, and with over two billion persons vaccinated, it has a long record of safe use. Variable efficacy of BCG has been observed, however, in different vaccine trials and the increase in drug-resistant TB cases worldwide suggests the need for an improved vaccine against TB.

The immunostimulatory properties of BCG...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry